Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression.

IF 9.4 1区医学 Q1 HEMATOLOGY Experimental Hematology & Oncology Pub Date : 2024-07-01 DOI:10.1186/s40164-024-00532-4

Yanyan Zhang, Charles Wang, Jian Jian Li

{"title":"Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression.","authors":"Yanyan Zhang, Charles Wang, Jian Jian Li","doi":"10.1186/s40164-024-00532-4","DOIUrl":null,"url":null,"abstract":"<p><p>Immune checkpoint blockade (ICB) necessitates a thorough understanding of intricate cellular interactions within the tumor microenvironment (TME). Mesenchymal stromal cells (MSCs) play a pivotal role in cancer generation, progression, and immunosuppressive tumor microenvironment. Within the TME, MSCs encompass both resident and circulating counterparts that dynamically communicate and actively participate in TME immunosurveillance and response to ICB. This review aims to reevaluate various facets of MSCs, including their potential self-transformation to function as cancer-initiating cells and contributions to the creation of a conducive environment for tumor proliferation and metastasis. Additionally, we explore the immune regulatory functions of tumor-associated MSCs (TA-MSCs) and MSC-derived extracellular vesicles (MSC-EVs) with analysis of potential connections between circulating and tissue-resident MSCs. A comprehensive understanding of the dynamics of MSC-immune cell communication and the heterogeneous cargo of tumor-educated versus naïve MSCs may unveil a new MSC-mediated immunosuppressive pathway that can be targeted to enhance cancer control by ICB.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":9.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11218091/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental Hematology & Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40164-024-00532-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immune checkpoint blockade (ICB) necessitates a thorough understanding of intricate cellular interactions within the tumor microenvironment (TME). Mesenchymal stromal cells (MSCs) play a pivotal role in cancer generation, progression, and immunosuppressive tumor microenvironment. Within the TME, MSCs encompass both resident and circulating counterparts that dynamically communicate and actively participate in TME immunosurveillance and response to ICB. This review aims to reevaluate various facets of MSCs, including their potential self-transformation to function as cancer-initiating cells and contributions to the creation of a conducive environment for tumor proliferation and metastasis. Additionally, we explore the immune regulatory functions of tumor-associated MSCs (TA-MSCs) and MSC-derived extracellular vesicles (MSC-EVs) with analysis of potential connections between circulating and tissue-resident MSCs. A comprehensive understanding of the dynamics of MSC-immune cell communication and the heterogeneous cargo of tumor-educated versus naïve MSCs may unveil a new MSC-mediated immunosuppressive pathway that can be targeted to enhance cancer control by ICB.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

重新审视间充质基质细胞在癌症诱发、转移和免疫抑制中的作用。

免疫检查点阻断（ICB）需要全面了解肿瘤微环境（TME）中错综复杂的细胞相互作用。间充质基质细胞（MSCs）在癌症的产生、发展和免疫抑制性肿瘤微环境中发挥着关键作用。在肿瘤微环境中，间充质干细胞既包括常住的，也包括循环的，它们动态地交流并积极参与肿瘤微环境的免疫监视和对 ICB 的反应。本综述旨在重新评估间充质干细胞的各个方面，包括其作为癌症启动细胞的潜在自我转化功能，以及为肿瘤增殖和转移创造有利环境所做的贡献。此外，我们还探索了肿瘤相关间充质干细胞（TA-MSCs）和间充质干细胞衍生的细胞外囊泡（MSC-EVs）的免疫调节功能，并分析了循环间充质干细胞和组织驻留间充质干细胞之间的潜在联系。全面了解间充质干细胞与免疫细胞之间的动态交流以及肿瘤教育间充质干细胞与天真间充质干细胞之间的异质性载体，可能会揭示出一种新的间充质干细胞介导的免疫抑制途径，从而可以有针对性地通过ICB加强对癌症的控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.